Artiva Biotherapeutics (ARTV) Research & Development (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Research & Development data on file, last reported at $19.3 million in Q1 2026.

• Research & Development for Q1 2026 came in at $19.3 million, up 13.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $71.8 million (up 27.7% YoY), and the FY2025 annual result was $69.5 million, up 38.17% from the prior year.
• Research & Development climbed to $19.3 million in Q1 2026 per ARTV's latest filing, from $17.0 million in the prior quarter.
• Over five years, Research & Development peaked at $19.3 million in Q1 2026 and troughed at $11.2 million in Q4 2023.
• A 4-year average of $14.6 million and a median of $13.4 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development advanced 3.51% in 2024, then soared 52.85% in 2025.
• A 4-year view of Research & Development shows it stood at $11.2 million in 2023, then climbed by 19.4% to $13.3 million in 2024, then advanced by 27.61% to $17.0 million in 2025, then advanced by 13.64% to $19.3 million in 2026.
• Business Quant data shows ARTV's Research & Development at $19.3 million in Q1 2026, $17.0 million in Q4 2025, and $17.6 million in Q3 2025.